To further evaluate the therapeutic efficacy of H1/AIM2 in RCC, the subcutaneous 786‐O‐xenograft model established in nude mice were intratumorally administrated with H1/pAIM2 or control. This evidence concerns the gene AIM2 and renal cell carcinoma.